Patients must not have any history of hypersensitivity to any drugs or metabolites of midostaurin Patients with a history of hypersensitivity reactions to prior chemotherapy administered for previous cancer diagnoses are eligible to participate in the study, unless the hypersensitivity reaction consisted of anaphylaxis not amenable to desensitization Patients with a history of hypersensitivity to nickel Patients with history of hypersensitivity to liposomal products Subjects with a history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins; or a history of prior acute hepatotoxicity attributable to phenytoin. Has a history of vasculitis. No history of severe hypersensitivity reaction to Cremophor EL History of severe hypersensitivity reactions to cisplatin or vinblastine or other products of the same class; Has a history of vasculitis. History of hypersensitivity to sertraline Any history of hypersensitivity to irinotecan History of severe hypersensitivity reactions, which in the opinion of the investigator may cause in increased risk of serious infusion reaction. Previous history of hypersensitivity to eggs or allergy or untoward reaction to prior vaccinia (smallpox) vaccination History of hypersensitivity to metformin or history of discontinuation secondary to attributed adverse effects History of hypersensitivity or idiosyncratic reactions to amide-type local anesthetics or opioids. History of clinical hypersensitivity to the immunotherapy proposed for combination treatment. A history of sun hypersensitivity or photosensitive dermatitis. History of infusion-related reactions and/or hypersensitivity to trastuzumab, (ado-)trastuzumab emtansine; History of hypersensitivity to thyrotropin alpha (Thyrogen) History of severe hypersensitivity reaction to Cremaphor EL Patients will not be eligible if they have a history of hypersensitivity to tranexamic acid Patients who have a history of ataxia telangiectasia or other documented history of radiation hypersensitivity History of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type reaction to Cremophor, or history of hypersensitivity type reaction to polysorbate or other components of the formulation of Oraxol History of hypersensitivity to cyclophosphamide, fludarabine or IL-. Patients with a history of hypersensitivity to bosutinib or axitinib History of hypersensitivity to any of the kinase inhibitors included in this study History of hypersensitivity to hydrogel. History of Subjects with history of hypersensitivity to azoles History of hypersensitivity to vemurafenib Patients with history of hypersensitivity to conductive hydrogel are not eligible Have a history of hypersensitivity to dacarbazine (DTIC) History or presence of hypersensitivity or idiosyncratic reaction to deferiprone or deferoxamine; History of hypersensitivity to a taxane History of hypersensitivity to cyclophosphamide, fludarabine or IL- The subject has a history of hypersensitivity reaction to temozolomide or a history of hypersensitivity to dacarbazine (DTIC) History of hypersensitivity to dacarbazine A history of ataxia telangiectasia or other documented history of radiation hypersensitivity History of: History of prior grade or hypersensitivity or any toxicity to trastuzumab that warranted permanent cessation of this antibody Subject has a history of hypersensitivity to porcine derived gelatin or collagen. Subject has a history of hypersensitivity to microbial Transglutaminase. Has a history of severe hypersensitivity reaction (e.g., generalized rash/erythema, hypotension, bronchospasm, angioedema or anaphylaxis) to axitinib or sunitinib. Current or past history of severe hypersensitivity to any other antibody products History of severe hypersensitivity reaction to taxanes History of hypersensitivity to anakinra. History of hypersensitivity to denosumab. History of hypersensitivity to everolimus. History of hypersensitivity to castor oil History of hypersensitivity to ibrutinib History of hypersensitivity to TPIV History of Known history of cardiomyopathy History of prior >= G hypersensitivity (HSR) or any toxicity to trastuzumab or pertuzumab that warranted permanent cessation of this agent History of severe hypersensitivity reaction (>= grade ) to docetaxel Patients with a history of grade >= hypersensitivity reaction to trastuzumab, OR grade >= with the most recent trastuzumab infusion before study entry, OR continued requirement for prolonged trastuzumab infusions to prevent hypersensitivity reactions are not eligible for participation History of hypersensitivity to any compound in the tetracycline antibiotics group History of hypersensitivity to ipilimumab Patients who have had a hypersensitivity reaction to polyoxyethylated or hydrogenated castor oil A history of ataxia telangiectasia or other documented history of radiation hypersensitivity History of hypersensitivity to sirolimus History of hypersensitivity to vorinostat History of hypersensitivity to hydroxychloroquine Any history of adverse reaction or hypersensitivity to LDAC History of hypersensitivity to -aminoquinoline compound A history of a severe hypersensitivity reaction to ipilimumab or dabrafenib History of suspected history, or presence of heparin induced toxicity (w/ or w/o thrombosis) History of hypersensitivity to hydrogel Prior history of cardiomyopathy. History of hypersensitivity to amikacin or other aminoglycosides History of hypersensitivity to taxanes or drug formulations containing Cremophor. Patients with a history of D mutations History of: History of hypersensitivity reactions attributed to simvastatin History of severe hypersensitivity reaction to capecitabine, -FU, temozolomide or DTIC will be excluded (i.e. anaphylaxis or anaphylactoid reactions) History of hypersensitivity to other psychostimulants Has a history of severe hypersensitivity reaction to pembrolizumab, Cisplatin or radiotherapy or their analogs History hypersensitivity to opioids. History of hypersensitivity or reaction to N-methyl-D-aspartate (NMDA) receptor antagonists Patient has a history of hypersensitivity to fentanyl or opioids PATIENTS: History of hypersensitivity to haloperidol or chlorpromazine History of hypersensitivity to pregabalin or gabapentin Patients with a history of echinocandin or fluconazole hypersensitivity are not eligible History of hypersensitivity to all of the following antibiotics: penicillin, erythromycin, clindamycin, and any fluoroquinolone History of hypersensitivity to haloperidol or benzodiazepine Prior history of acupressure use No history of severe hypersensitivity reactions to drugs or other causes (e.g., beestings) History of phenylketonuria (PKU) Previous medical history of, or suspected hypersensitivity to, the Methylene Blue and/or formulations' ingredients. History of hypersensitivity to previous influenza vaccination or severe or moderate hypersensitivity to eggs/egg protein History of hypersensitivity to previous influenza vaccination or severe or moderate hypersensitivity to eggs/egg protein History of hypersensitivity or idiosyncratic reactions to azoles History of hypersensitivity reaction to Xolair or any ingredient of Xolair History of hypersensitivity to taxanes; hypersensitivity to the solvent does not preclude patient participation in this Study History of hypersensitivity or unexpected reactions to capecitabine, other fluoropyrimidine agents, or any of their ingredients History of relapse of ALL History of hypersensitivity to nickel History of iritis or episcleritis. The patient received omacetaxine or has a history of hypersensitivity. Patients with a history of hypersensitivity to nickel. History of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type reaction to Cremophor